SofWave Medical is a technology company.
SofWave Medical has raised $8.0M across 1 funding round.
SofWave Medical has raised $8.0M in total across 1 funding round.
SofWave Medical has raised $8.0M in total across 1 funding round.
SofWave Medical's investors include Alon MedTech Ventures.
Sofwave Medical is an Israeli aesthetic medicine company headquartered in California, publicly traded on the Tel Aviv Stock Exchange (TASE: SOFW), specializing in non-invasive ultrasound-based treatments for skin rejuvenation.[1][2] It develops and sells the Sofwave™ system, which uses Synchronous Ultrasound Parallel Beam (SUPERB™) technology to stimulate collagen, elastin, and hyaluronic acid production, addressing wrinkles, facial lines, skin laxity, and cellulite appearance in a single 30-45 minute session with no downtime.[1][2][4] The device targets providers like dermatologists and serves patients seeking safe, FDA-cleared treatments for all skin types, particularly those avoiding invasive procedures; growth is evidenced by regulatory clearances (FDA, CE, TGA) and clinical results showing improvements at 3 months post-treatment.[1][2][4]
Sofwave Medical was founded in 2015 by Dr. Shimon Eckhouse (chairman) and Ariel Sverdlik (CTO) within the Alon Medtech Ventures incubator in Yokneam, Israel, supported by the Israel Innovation Authority.[1] Eckhouse, often called the "father of the medical aesthetics field in Israel," brings extensive experience from founding and investing in companies like Lumenis (sold for $1.2 billion) and Syneron Medical (reached $1 billion market cap, both Nasdaq-listed).[1] The core Synchronous Ultrasound Parallel Beam technology was invented by Eckhouse and Sverdlik, emerging from their expertise to create a non-invasive alternative for dermatological treatments; early development focused on FDA clearance and clinical validation, leading to commercial rollout.[1][2]
Sofwave rides the surge in regenerative aesthetics, where demand for non-invasive, natural-looking anti-aging solutions grows amid rising consumer preference for downtime-free treatments over surgery or injectables.[2][5] Timing aligns with ultrasound advancements in medtech, fueled by an aging global population and $15B+ aesthetics market expansion; Israeli innovation hubs like Yokneam amplify its edge in R&D.[1] Market forces favor it via broad regulatory nods and inclusivity for diverse skin types, reducing barriers versus laser alternatives; it influences the ecosystem by enabling dermatologists to offer scalable, high-margin procedures, accelerating adoption in competitive clinics.[1][2][3][5]
Sofwave is poised for expansion through international rollouts, new indications like body contouring via Pure Impact™, and deeper penetration in underserved markets for inclusive aesthetics.[2] Trends like AI-enhanced personalization and combo therapies with EMS/ultrasound will shape its trajectory, potentially boosting revenue as tele-dermatology and at-home adjuncts evolve. Its influence may grow via Eckhouse's track record, evolving from niche player to medtech staple—cementing non-invasive ultrasound as the go-to for effortless skin regeneration, much like its founders redefined aesthetics before.[1][2]
SofWave Medical has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in August 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2019 | $8.0M Series A | Alon MedTech Ventures |